Introduction

57
The most commonly affected site in Crohn's Disease (CD) is the terminal ileum (26) with 58 progressive stricturing due to fibrostenosing type disease (FCD) a major indication for 59 surgery. The cumulative probability of surgery in patients with CD is approximately 10% 60 annually (30), with 70-90% of patients ultimately requiring surgery (14, 25, 36) .
61
Intestinal stricturing in CD involves gross thickening of the bowel wall, attributable in 62 particular to expansion of the submucosal and seromuscular (reticular) regions. Thickening in 63 the latter is characterised by the presence of an expanded population of activated fibroblasts 64 organised into discrete areas of scar tissue, and embedded within extensively infiltrated and 65 hypertrophied mesenteric fat (27, 32) . Elucidation of the key steps operative in fibroblast 66 activation and subsequent scar formation in FCD holds the potential to identify new 67 molecular targets for novel anti-fibrotic therapies (6).
68
Fibroblasts derived from stricture sites have an altered phenotype which persists during Consequently, S100A4 has increasingly been adopted as a marker of EMT in studies that 99 attempting to define the contribution of this process to chronic tissue remodelling. Significant 100 disagreement exists in the literature as to whether S100A4 overexpression during chronic 
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The aim of the present study was to characterise and quantify the expression of S100A4 in 107 the strictured ileum of patients undergoing ileocaecal resection for FCD. Specific emphasis 108 was placed on the presence of S100A4 in lineages likely to directly contribute to stricture 109 formation, namely the mucosal epithelial cells (via EMT) and intestinal fibroblasts. The 110 effect of si-RNA mediated S100A4 depletion on the migratory potential of intestinal 111 fibroblasts in vitro was subsequently examined.
112
Materials and Methods
113
Patient cohort
114
Samples from 8 patients with FCD were identified for study ( Polysciences Europe GmbH, Eppelheim, Germany), and 0.5% acetic acid. Sections were then 132 dehydrated, mounted, and cover-slipped.
133
Immunohistochemical Studies
134
Prior to primary antibody incubation, 4μm sections were deparaffinised, endogenous 135 peroxidase quenching was carried out in 3% hydrogen peroxide in methanol and antigen 136 retrieval performed in 0.5M citric acid buffer. Sections were probed for S100A4 (polyclonal 137 rabbit anti-human, A5114, Dako, Ireland) , CD3 (polyclonal goat anti-human CD3δ chain, epithelial cells by measuring the width (nm) of junctions at 5 cell-cell adhesion sites.
166
Quantification was repeated over 3 discrete locations in the mucosa. All images were 167 calibrated and recorded using a MegaView 3 digital recording system (Olympus).
168
Fibroblast Isolation and Culture
169
Intestinal fibroblast cultures were established using a primary explant technique as previously DNase I then used to synthesize cDNA using the random primer method.
188
Gene target expression was analysed using real-time PCR TaqMan assay on an ABI PRISM 
200
Protein Extraction and Western Blot Analysis
201
Total protein was isolated from snap-frozen CD mucosa by homogenisation in tissue lysis 202 buffer as previously described (12). Total protein from fibroblast culture was isolated using
203
RIPA buffer also as previously described (1 
277
Mucosal S100A4 positivity is concentrated in the lamina propria in grossly Normal tissue 278 sections (Fig. 4, a and b) . A similar profile is found in diseased sections, in which staining 279 also becomes prominent in cells continuous with the mucosal epithelium (Fig. 4 c and d) .
280
Similar patterns of staining are observed to S100A4 when stained with CD3 (Fig. 4e) ,
281
suggesting that they are T-lymphocytes (arrow in e), Pan-cytokeratin staining (Fig. 4f) 
299
Confluent paired sets of fibroblasts show a 4.9-fold increase in S100A4 mRNA levels (1 +/-300 1.9 vs. 4.9 +/-1.6, p< 0.01) from disease-derived explants on real-time RT-PCR analysis 301 (Fig. 6A ). Western blotting analysis shows a striking increase in S100A4 protein expression 302 in diseased fibroblast explants (Fig. 6B) . 
306
Primary culture of fibroblasts from proximal normal resection margins were treated with the 307 pro-fibrotic cytokine TGF-β1 (1ng/ml) for 24 hours. This led to a 2.9-fold increase in 308 S100A4 mRNA expression (1 +/-1.2 vs. 2.9 +/-0.6, *p< 0.01) (Fig. 7A) . Treatment of CCD- Normal adjacent margin fibroblast explant cultures were treated with TGF-β1 (1ng/ml),
317
causing a significant increase in migratory capacity at 24 hours (p< 0.01) (Fig. 8A) . The 318 effect of S100A4 si|RNA (si-S100A4) on basal and TGF-β1 induced fibroblast migration was 319 then examined in CCD-18 Co fibroblasts (Fig. 8B) . The si-S100A4 alone caused a reduced 320 migratory capacity at 24 hours versus control and scrambled siRNA treatments (p< 0.01) and 321 was equally effective at inhibiting TGF-β1 enhancement of migration (p< 0.01). This study examined the expression profile of S100A4 in the strictured ileum of patients with
341
FCD, in order to establish whether S100A4 might be implicated as a component of EMT
342
and/or fibroblast activation, as previously reported in diverse disease states (17, 18, 34, 42) .
343
S100A4 expression was increased in the mucosa at stricture sites, principally within the 344 lamina propria but also in cells continuous with the mucosal epithelium, that appear to be 345 intra-epithelial T-lymphocytes. S100A4 expression was also observed in α-SMA negative 346 fibroblasts populating discrete areas of scar within the expanded fibrofatty tissue of the 347 strictured ileum. Constitutive increases in S100A4 expression in fibroblast explants obtained 348 from these sites were also found. S100A4 upregulation was observed in intestinal fibroblasts 349 treated with TGF-β1 and upregulation was required for the migratory response to scratch 350 wounding.
351
The increased levels of S100A4 in immune cells observed in the strictured mucosa are 352 consistent with reports of S100A4 expression in activated T-lymphocytes and macrophages
353
in breast cancer (7), and co-localisation of S100A4 with the common leukocyte antigen CD45 structure would seem to be low.
380
Fibroblastic S100A4 expression was observed within scar tissue in the fibrofatty layer of the 381 bowel wall of diseased segments of FCD resections. The possibility that S100A4 staining 382 fibroblasts might also be found in the lamina propria and submucosa cannot be excluded,
383
however the density of S100A4-positive cells, and the difficulty with which myofibroblasts 384 and apical projections of the muscularis mucosae can be differentiated in the lamina propria,
385
led the authors to focus on the more delineated areas of scar in the fibrofatty tissue. These 386 S100A4 positive fibroblasts were α-SMA negative, indicating that they did not have 387 myofibroblast or smooth muscle phenotype and were highly unlikely to be derived from 388 muscle hyperplasia. This suggests that they represent a different subtype from the lamina 389 propria myofibroblast, in which several functional studies have been carried out (20, 22, 28, 390 29, 41). The existence of an S100A4 positive, α-SMA negative subpopulation of activated 391 fibroblasts has been described both in the tumour associated stroma of murine models of 392 pancreatic and breast cancer (44) 
397
The principal cellular behaviour associated with S100A4 is migration. The major identified 
404
The scratch wound healing assay provides a convenient method of assessing migration in 405 cultured fibroblasts (24). The migratory capacity of intestinal fibroblasts in this assay was 406 enhanced by TGF-β1 and was dependent upon S100A4 expression. This finding implies a 407 role for increased expression of S100A4 in the migratory potential of fibroblasts in FCD. 
426
Ligation of the proposed extracellular receptor for S100A4, the RAGE receptor, has been 427 shown to effect Smad3 activation in a TGF-β receptor independent manner (23); therefore, that extracellular S100A4 increases migratory capacity in a RAGE dependent manner (40).
437
The present data indicate that S100A4 may play a role during stricture formation in FCD as a 
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